Clavis Pharma raises USD 20 million in a private placement to fund further development of its anticancer drug pipeline
The Private Placement took place through a bookbuilding process and was managed by Carnegie ASA and DnB NOR Markets as joint-lead managers and joint bookrunners. The Private Placement, which represents approximately 80% of the current outstanding share capital, was well oversubscribed at the issue price and was supported by existing life science and institutional investors, including NeoMed Management and MVM Life Science Partners, as well as new institutional investors.
The net proceeds to the Company from the Private Placement will provide financial resources to achieve key clinical data on its products in development, and optimise its commercial strategy. More specifically, the Company intends to use the net proceeds to:
i) Obtain randomised data from clinical studies for lead products
a. Complete first part of a Phase II/III registration study for elacytarabine in leukaemia (AML)
b. Complete a randomised Phase II study with IV CP-4126 in pancreatic cancer
c. Complete Phase I study for Oral CP-4126 in various solid cancers
ii) Achieve pre-clinical proof of concept for CP-4200
iii) Place the company in a position of strength from which to negotiate appropriate partnership agreements as well as for general corporate purposes
Completion of the Private Placement is conditional upon approval by the Company's Extraordinary General Meeting to be held on or about 15 July 2009. Shareholders representing more than the required two thirds of the shares have irrevocably undertaken to vote in favour of the Private Placement at the EGM.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.